Moolec Science Receives Determination Letter From Nasdaq

November 21, 2025 / On November 14, 2025, Moolec Science SA ("Moolec" or the "Company") received a determination letter (the "Nasdaq Determination Letter") from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the closing bid price of the Company's ordinary shares had been below the minimum $1.00 per share requirement for the last 30 consecutive business days, as set forth in Nasdaq Listing Rule 5550(a)(2), and informing the Company of their view that the Company would not be afforded an automatic 180-day period to regain compliance with such rule.

The Company has submitted a timely appeal to a Nasdaq Hearings Panel, through which it will request the granting of a 180- day period to submit and effect a compliance plan, which will include a potential implementation of a reverse stock split, if determined to be in the best interest of shareholders.

The submission of the appeal automatically stays the effect of the Nasdaq Determination Letter until the appeal has been considered, which will take place on December 18, 2025. Accordingly, the Company's ordinary shares will continue to trade on The Nasdaq Capital Market under the symbol "MLEC" without interruption during such stay.

The Company intends to continue closely monitoring the closing bid price for its ordinary shares and remains committed to evaluating and executing all appropriate actions to cure the deficiency and regain compliance with Nasdaq Listing Rule 5550(a)(2). The receipt of the Nasdaq Determination Letter does not affect the Company's business, operations or reporting requirements with the Securities and Exchange Commission.